Literature DB >> 17297438

Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A.

J Ma1, H K Arnold, M B Lilly, R C Sears, A S Kraft.   

Abstract

The Pim protein kinases are serine threonine protein kinases that regulate important cellular signaling pathway molecules, and enhance the ability of c-Myc to induce lymphomas. We demonstrate that a cascade of events controls the cellular levels of Pim. We find that overexpression of the protein phosphatase (PP) 2A catalytic subunit decreases the activity and protein levels of Pim-1. This effect is reversed by the application of okadaic acid, an inhibitor of PP2A, and is blocked by SV40 small T antigen that is known to disrupt B subunit binding to PP2A A and C subunits. Pim-1 can coimmunoprecipitate with the PP2A regulatory B subunit, B56beta, but not B56alpha, gamma, delta, epsilon or B55alpha. Using short hairpin RNA targeted at B56beta, we demonstrate that decreasing the level of B56beta increases the half-life of Pim-1 from 0.7 to 2.8 h, and decreases the ubiquitinylation level of Pim-1. We also find that Pin1, a prolyl-isomerase, is capable of binding Pim-1 and leads to a decrease in the protein level of Pim-1. On the basis of these observations, we hypothesize that phosphorylated Pim-1 binds Pin1 allowing the interaction of PP2A through B56beta. Dephosphorylation of Pim-1 then allows for ubiquitinylation and protein degradation of Pim-1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297438     DOI: 10.1038/sj.onc.1210323

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

Review 1.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

2.  p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.

Authors:  Marina Zemskova; Michael B Lilly; Ying-Wei Lin; Jin H Song; Andrew S Kraft
Journal:  Mol Cancer Res       Date:  2010-07-20       Impact factor: 5.852

3.  Protein phosphatase 2A acts as a mitogen-activated protein kinase kinase kinase 3 (MEKK3) phosphatase to inhibit lysophosphatidic acid-induced IkappaB kinase beta/nuclear factor-kappaB activation.

Authors:  Wenjing Sun; Hao Wang; Xiumei Zhao; Yang Yu; Yihui Fan; Hao Wang; Xishan Wang; Xiongbin Lu; Guiyin Zhang; Songbin Fu; Jianhua Yang
Journal:  J Biol Chem       Date:  2010-05-06       Impact factor: 5.157

Review 4.  PP2A as a master regulator of the cell cycle.

Authors:  Nathan Wlodarchak; Yongna Xing
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-02-24       Impact factor: 8.250

Review 5.  PIM kinase (and Akt) biology and signaling in tumors.

Authors:  Noel A Warfel; Andrew S Kraft
Journal:  Pharmacol Ther       Date:  2015-03-05       Impact factor: 12.310

Review 6.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 7.  Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins.

Authors:  Yih-Cherng Liou; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Trends Biochem Sci       Date:  2011-08-17       Impact factor: 13.807

Review 8.  Pim-1 kinase inhibits pathological injury by promoting cardioprotective signaling.

Authors:  Kimberlee M Fischer; Christopher T Cottage; Mathias H Konstandin; Mirko Völkers; Mohsin Khan; Mark A Sussman
Journal:  J Mol Cell Cardiol       Date:  2011-01-19       Impact factor: 5.000

Review 9.  The eNOS signalosome and its link to endothelial dysfunction.

Authors:  Mauro Siragusa; Ingrid Fleming
Journal:  Pflugers Arch       Date:  2016-05-17       Impact factor: 3.657

10.  Discovery and identification of PIM-1 kinase inhibitors through a hybrid screening approach.

Authors:  Mingfeng Shao; Yiming Yuan; Kun Yu; Kai Lei; Guonian Zhu; Lijuan Chen; Mingli Xiang
Journal:  Mol Divers       Date:  2014-02-12       Impact factor: 2.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.